HK Stock Market Move | SIHUAN PHARM (00460) rose nearly 4%. Recently, a new specification of the childlike needle has been approved and launched, further improving the layout of regenerative medical beauty products.

SIHUAN PHARM(00460) rose nearly 4%, rising 3.94% to HK$1.32 as of the time of writing, with a trading volume of HK$12.825 million. On the news front, recently, SIHUAN PHARM announced that its subsidiary Meiyanking Space Biotechnology (Jilin) Co., Ltd. independently developed six new specifications of polylactic acid facial filler (marketed as "Childlike Face Needle") have been officially approved by the China National Medical Products Administration. This is another important development after the product was first approved, further improving the company's market layout in the field of regenerative medical beauty products. Prior to this specification expansion, the product had been approved for three specifications: 45mg per bottle, 75mg per bottle, and 150mg per bottle, respectively suitable for different needs such as preventive management, combined therapy, and comprehensive rejuvenation. The newly approved six new specifications of 60mg per bottle, 80mg per bottle, 100mg per bottle, 110mg per bottle, 120mg per bottle, and 130mg per bottle will further enrich the product range.